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Human vaccines are delivered through skin, com-
monly by the s.c. route, allowing access to a rich 
network of DCs in skin and skin-draining LNs 
(Romani et al., 2010). s.c. injected vaccine antigens 
reach LNs that drain the skin and epithelial sur-
faces by passive transport through lymphatics or 
by DC antigen capture followed by subsequent 
cell-bound trafficking to the LNs, where T cell 
priming occurs (Itano et al., 2003). Resident 
DCs and several distinct migratory DC subsets 
(migDCs) that traffic to LN from skin are pres-
ent in LNs (Förster et al., 1999; Henri et al., 
2010b). The current paradigm is that both LN-
resident DCs and migDCs have access to s.c. de-
livered antigen, are requisite, and cooperate to 
induce immunity (Itano et al., 2003; Allenspach 
et al., 2008). Based on this paradigm, vaccinol-
ogy efforts have focused heavily on delivery of 
antigens to skin-resident DCs.
Flt3L is a DC hematopoietin that maintains 
DC numbers at set levels throughout adult life 
(Liu et al., 2007, 2009) and at sites relevant to 
vaccination, including the skin and skin-draining 
LN (Brasel et al., 1996; Maraskovsky et al., 
1996). In healthy individuals, Flt3L is tightly 
regulated and at the limits of detection by ELISA; 
notably, it is 20-fold lower than CSF-1 or c-kit 
ligand (Shadle et al., 1989; Langley et al., 1993; 
Lyman and McKenna, 2003). Flt3L is secreted 
during acute infection, however, leading to DC-
mediated support of NK function (Eidenschenk 
et al., 2010; Guermonprez, 2012). During s.c. 
immunization, the composition of DC subsets 
in the skin-draining LNs is transiently altered 
(Kastenmüller et al., 2011). It is unknown if Flt3L 
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DCs are critical for initiating immunity. The current paradigm in vaccine biology is that DCs 
migrating from peripheral tissue and classical lymphoid-resident DCs (cDCs) cooperate in 
the draining LNs to initiate priming and proliferation of T cells. Here, we observe subcuta-
neous immunity is Fms-like tyrosine kinase 3 ligand (Flt3L) dependent. Flt3L is rapidly 
secreted after immunization; Flt3 deletion reduces T cell responses by 50%. Flt3L enhances 
global T cell and humoral immunity as well as both the numbers and antigen capture ca-
pacity of migratory DCs (migDCs) and LN-resident cDCs. Surprisingly, however, we find immu-
nity is controlled by cDCs and actively tempered in vivo by migDCs. Deletion of Langerin+ DC 
or blockade of DC migration improves immunity. Consistent with an immune-regulatory 
role, transcriptomic analyses reveals different skin migDC subsets in both mouse and human 
cluster together, and share immune-suppressing gene expression and regulatory pathways. 
These data reveal that protective immunity to protein vaccines is controlled by Flt3L-
dependent, LN-resident cDCs.
© 2014 Anandasabapathy et al. This article is distributed under the terms of an 
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after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
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and MDA5 (Gitlin et al., 2006). To assess if Flt3 signaling was 
required, we compared prime-boost immunization with 0.5 µg 
CD205-gag p24 vaccine with GLA-SE in control versus 
Flt3/ mice. Flt3/ mice consistently had 50% lower vaccine 
responses (Fig. 1 B). Collectively, these data suggest Flt3L is se-
creted after adjuvant administration with protein immuniza-
tion and Flt3 signaling is required for optimal immunity.
To assess the impact of Flt3L on s.c. immunization, we 
treated mice with Flt3L or PBS surrounding prime-boost im-
munization with GLA-SE (Fig. 1 C). Upon antigen recall, we 
observed markedly increased IFN- production in CD4+ 
T cell isolated from spleen when challenged with HIV-gag 
p24, but not control p17 peptides (Fig. 1 D and Fig. S1, gating). 
Flt3L-treated mice had enhanced antigen-specific clonal ex-
pansion in vitro (CFSElow, IFN-+) and enhanced CD4 T cell 
IFN- responses ex vivo when isolated from draining LNs, 
lung parenchyma, and small intestinal lamina propria as assayed 
by intracellular cytokine staining (ICS). Improved titers of 
serum IgG directed against gag p24 were observed. To deter-
mine if Flt3L-improved protein immunization is adjuvant spe-
cific, we also tested polyIC(LC) as adjuvant (Fig. 1 E). We again 
observed enhanced CD4 IFN- recall, CD4+ clonal expan-
sion, mucosal immunity, and HIV gag p24-specific IgG titers.
To determine if Flt3L potentiates both soluble and DC-
targeted protein vaccines, we immunized mice with soluble 
versus CD205-targeted gag p24 and GLA-SE. Flt3L im-
proved soluble and DC-targeted responses (Fig. 2 A). At high 
antigen dose (5 µg) irrespective of Flt3L treatment, no differ-
ence was observed when comparing soluble to targeted vac-
cine responses. However, at 0.5 µg, antibody-mediated antigen 
targeting imparted a significant benefit to immunization. This 
effect was not dose-sparing, as targeted vaccination irrespec-
tive of Flt3L treatment resulted in improved clonal prolifera-
tion with respect to soluble antigen (Fig. 2 B). Similar trends 
were noted in mucosa and LNs (unpublished data). Thus, Flt3L 
improves both DC-targeted and nontargeted protein immu-
nization. We established that targeting specificity through 
CD205 occurred at 0.5 µg as soluble protein immunization 
lacked a discernible response at 0.5 µg (Fig. 2, A and B).
Although CD205-gag p24 priming in primates induces 
both CD4 and CD8 immunity, in B6 mice we observe only 
CD4+ priming due to epitope restriction (Trumpfheller et al., 
2008). To assess Flt3L treatment on cross-presentation to CD8+  
T cells, we examined polyclonal CD8+ T cell responses after 
immunization to CD205-OVA with polyIC(LC). CD8+ 
T cell IFN- was assayed using mixed OTI and II recall peptides 
and p24-pooled peptide controls. When assayed from lung pa-
renchyma, spleen, and lamina propria, T cells from Flt3L mice 
had increased CD8+ T cell IFN- production, proliferation, 
and IgG titers to OVA (Fig. 2 C). Therefore, we conclude 
Flt3L enhanced cross-presentation to CD8+ T cells.
Flt3L expands CD205+ LN-resident cDCs and migratory  
DCs and enhances in vivo CD205-based antigen capture
To better understand the possible mechanisms underlying Flt3L 
enhancement of s.c. immunization, we examined the effect of 
is secreted during immunization to regulate DC expansion 
acutely or if Flt3 signaling is required for productive immunity.
Flt3L and its receptor (Flt3, FLK2) instruct progenitors 
along a DC developmental pathway regulating the mobilization 
of preDCs from the blood to give rise to IFN-–producing 
PDC, CD8+, and CD8neg cDCs in lymphoid organs and 
tissue-resident DCs such as Langerin+CD103+ DCs in skin 
(Waskow et al., 2008). Lymphoid CD8+ (Bozzacco et al., 2010) 
and tissue CD103+ DCs both cross-present antigens (the major 
pathway of tumor and viral antigen presentation), derive from 
preDCs (Ginhoux et al., 2009), and share Flt3L developmental 
dependence (Liu et al., 2009), with common regulation down-
stream of Flt3 by mTOR (Sathaliyawala et al., 2010). These 
findings suggest DC ontogeny may dictate function, one ra-
tionale for the use of hematopoetins to selectively drive DC 
development for clinical use. Flt3L is being reintroduced to 
the clinic to potentiate human vaccines. It is unclear if bias by 
Flt3L to cross-presenting DCs from skin and LN may be ex-
ploited for protein-based vaccine delivery. Also, Langerin+ 
CD103+ DCs, which are tissue-resident migDCs originating 
from skin, are specialized to cross-present viral antigens to T cells 
during cytolytic infection (Bedoui et al., 2009a). However, their 
role in immunization to viral antigens has not been established.
We observe Flt3 is required for robust immunity to s.c. im-
munization and can enhance immunity. Surprisingly, we find 
that irrespective of Flt3L treatment, migDCs in the LN (includ-
ing Langerin+ CD103+ cross-presenting DCs) are not required 
for CD4+ T cell effector function, despite having greater effi-
ciency of s.c. protein capture in the LN than resident CD8 
cDCs. Impairing DC migration from skin to the sdLN via 
knockout of the CCR7 receptor and deletion of migDC subsets 
including Langerin+CD103+ DCs enhanced, not diminished, 
immune priming. Rather, the immune response develops 
through CD11c+ ZBTB46-dependent cDCs. Transcriptomics 
in mouse and human reveal migDC subsets from skin relate 
most closely to each other and share gene signatures related to 
dampening of DC and T cell activation. Thus, we demonstrate 
that the immune response is controlled by cDCs in lymphoid 
tissue and that tissue microenvironment may confer immuno-
suppressive DC function in vivo.
RESULTS
s.c. immunity is Flt3L dependent
To assess if Flt3L is detected after immunization, we compared 
serum murine Flt3L levels by ELISA before and after immuni-
zation with adjuvant and a vaccine that targets protein antigens 
to DCs in vivo using antibodies directed against the C-type 
lectin CD205. Elevated Flt3L was detected in serum within 1 h 
of administering adjuvant with 0.5 µg of HIV gag p24-CD205 
fusion antibody (CD205-gag p24; Fig. 1 A). As adjuvant, 
we tested both GLA-SE (glucopyranosyl lipid adjuvant-stable 
emulsion), which acts through TLR4 (Duthie et al., 2011; Pantel 
et al., 2012), and the adjuvant polyIC(LC) (polyinosinic-
polycytidylic acid stabilized with polylysine double-stranded 
RNA and carboxymethylcellulose), which is a double-stranded 
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and intracellular CD205 staining). In vitro CD8 cDC capture 
of CD205 was almost 100% efficient at 1 and 3 h, and the per-
centage of cDCs that captured CD205 in vitro was increased 
by Flt3L due to higher representation of this population (Fig. 3 C; 
from 44 to 67%). This corresponded closely to the shift in total 
percentage of CD205+ cells (Fig. 3 B). Flt3L also contributed 
to an overall expansion of total migDCs.
Five phenotypically distinct migDC populations traffic 
from skin to draining LN (Henri et al., 2010a,b). Langerin+ 
Flt3L on DC subsets in the skin-draining LNs of Flt3L-treated, 
control, and Flt3L/ mice (Fig. S2, A and B, gating). Flt3L 
markedly increased PDCs and cDCs in skin-draining LNs 
(Fig. 3, A and B). PDCs are CD205 and PDCA1+ (unpub-
lished data). Within cDCs, we observed consistent expansion of 
CD8+ CD11blow and CD8neg CD11bhigh cDC numbers. 
CD205+ CD8+ DCs comprise 40% of CD8+ cDCs in the 
skin-draining LNs. Upon Flt3L treatment, CD205+ CD8+ 
cDCs cells were enriched to 73% of cDCs (Fig. 3 B; cell surface 
Figure 1. s.c. immunity is Flt3L depen-
dent. (A) Serum from n = 3–5 mice taken 
before (0 h) or at 1, 3, 6, 24, or 48 h after s.c. 
immunization with 0.5 µg of CD205 gag-
p24 and GLA (blue) or polyIC(LC) (red). Error 
bars show mean ± SD. (B) CD4+ IFN-+ intra-
cellular cytokine staining from 3 pooled  
experiments of 4–5 individual WT versus 
Flt3/ mice after s.c. vaccination with GLA + 
0.5 µg CD205 gag-p24. Open, filled, and 
patterned symbols depict individual ex-
periments. Error bars show mean ± SEM  
(P ≤ 001). (C) Schematic of vaccine immuni-
zation schedule and Flt3L versus PBS treat-
ment. (D) CD4+ T cell immunity at lymphoid 
and mucosal sites and humoral immunity 
after protein immunization to HIV-gag with 
multiple adjuvants: GLA (D) and polyIC(LC) 
(E). CD4+ IFN-+ intracellular cytokine stain-
ing from splenocytes of individual mice s.c. 
vaccinated with adjuvant + 5 µg CD205 
gag-p24 in spleen, LN, lamina propria, and 
lung. CD4+ IFN-+ + CFSE divided T cells 
after 96 h from individual immunized mice 
depicted in spleen. Circles represent indi-
vidual mice, open versus filled (pooled  
from 2 independent experiments, 3–5 mice 
per group). Error bars show mean ± SEM.  
*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001. Gag-p24 
serum total IgG in Flt3L-treated versus un-
treated mice, mean ELISA OD450, unimmu-
nized controls. Error bars show mean ± SEM 
across 5 individual mice from 1 representa-
tive experiment. *, P ≤ 0.05; **, P ≤ 0.01;  
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After Flt3L treatment, a small decrease in in vitro capture of 
CD205 by migDCs was apparent (from 75 to 69%; Fig. 3 E). 
To determine if migDCs and LN-resident cDCs in the nodes 
have equal access to antigen in vivo, we compared fluor-
escently labeled CD205 capture 3 h after s.c. injection into 
Flt3L-treated and untreated mice (Fig. 3 F). MigDCs captured 
antigen with greater efficiency than cDCs by CD205-A647 
label in the proximal LNs (popliteal), irrespective of Flt3L 
treatment. Flt3L improved CD205-A647 label by both 
migDCs in the distal LNs (inguinal) and cDCs in the proximal 
subsets include Langerhans cells (LCs), CD103+ Langerin+ 
dermal DCs, and the very rare CD103 Langerin+ DCs. 
Langerin subsets include CD11b+ DCs and CD11b DCs. 
Although some increase in Langerin+ CD103+ DCs occurred 
after Flt3L treatment, we have observed the major expansion 
of migDCs was seen in the CD11b+ and CD11b compart-
ment (Fig. 3 D; Mollah et al., 2014). Thus, Flt3L biases cDCs in 
the cutaneous LN toward CD8 CD205+ differentiation and 
expands migratory CD11b+, CD11b, and CD103+ Langerin+ 
DCs. MigDCs express high levels of CD205+ (Fig. 3 D). 
Figure 2. Flt3L potentiates both soluble and targeted vaccine priming and improves polyclonal CD8+ T cells responses and humoral immu-
nity to OVA cross-presentation. Vaccine priming with CD205-gag-p24 and soluble p24 at high (5 µg) and low (0.5 µg) doses in Flt3L-treated (red) 
versus PBS-treated (blue) mice. (A) Intracellular cytokine stain. (B) Proliferation of CD4+ T cells measured by CFSE-diluted IFN-+ cells. One representative 
experiment (n = 3 mice per group). Error bars show mean ± SEM. ^, P ≤ 0.1; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001. (C) CD8+ IFN-+ intracellular cytokine 
staining from individual mice vaccinated with polyIC(LC) + 5 µg CD205 OVA intraperitoneal route in spleen, lung, and lamina propria (n = 4–6 mice 
pooled from 2 independent experiments). CD8+ IFN-+ CFSE low/divided T cells at 96 h. One of two representative experiments (n = 5). Error bars show 
standard error of the mean. CD8+ IFN-+ intracellular cytokine staining. OVA serum total IgG, mean ELISA OD450. Error bars show mean ± SEM across  
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Figure 3. Flt3L expands classical, migratory, and plasmacytoid DC subsets in the skin draining LN and enhances antigen capture by CD205+ 
migratory and LN-resident cDCs in vivo. (A) Flt3L-treated (left) compared with WT (middle) and Flt3L/ mice (right). One representative experiment (of 
three) with sample quantitation of DC subsets for two pooled skin-draining LNs. Error bars show standard deviation between 3 mice. ^, P ≤ 0.1; *, P ≤ 0.05;  
**, P ≤ 0.01; ***, P ≤ 0.001. (B) Representative CD8+ CD11b low and CD8 CD11b high DC subset gating, from classical (cDCs) gate of skin draining LN from 
mice treated with Flt3L (left) or controls (right). Total % CD205 positive cells from within CD8+ CD11b low cDC subset (cell surface and intracellular stain-
ing). (C) In vitro capture of CD205 with equivalent total skin draining LN cells from Flt3L-treated versus PBS mice gated on total LN cDCs versus CD8 cDCs. 
One representative experiment of two with n = 3 mice per group, error bars depict SEM. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001. (D) Skin draining LN migratory 
DC subsets from within IAIEhi CD11cintermediate population from mice treated with Flt3L (left) or controls (right). CD103+ gating from within Langerin+ subset. 
CD205 cell surface and intracellular staining from migratory subsets (flow cytometry). (E) In vitro capture of CD205+ with equivalent total skin draining LN 
cells from Flt3L-treated versus PBS mice, gated on migDC. 1 representative experiment of 2 with n = 3 mice per group, error bars depict SEM. *, P ≤ 0.05;  
**, P ≤ 0.01; ***, P ≤ 0.001. (F) CD205-A647 versus Isotype-A647 control antibody was injected by s.c. immunization in the footpad of control versus Flt3L-
treated recipients (n = three mice per group, one representative experiment of three, one representative FACS plot shown). At 3 h, draining (popliteal) versus 
distal (inguinal) LNs were harvested and migratory versus conventional DC subsets were gated for antibody uptake.
(popliteal) LNs (Fig. 3 F), suggesting improved antigen cap-
ture in vivo. Thus, in vivo migDCs in LNs captured and inter-
nalized CD205 more rapidly than cDCs, and Flt3L improved 
antigen uptake by both.
s.c. immunization does not depend on Langerin+ DCs, 
including Langerin+ CD103+ DCs
Previous work suggested that migratory DCs initiate immune 
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Blockade of migratory DC entry to the LN enhances,  
not inhibits, s.c. and i.d. immunization
As described, steady-state migration of DCs from the skin to 
the draining LN depends on expression of the chemokine re-
ceptor CCR7. Mice that lack CCR7 demonstrate a complete 
absence of migDCs in the LN (Förster et al., 1999; Ohl et al., 
2004) irrespective of Flt3L treatment (Fig. 5 A). To further ad-
dress the contribution of migDCs to s.c. protein vaccination in 
the LN, we examined vaccine responses in CCR7/ mice. 
This allowed us to test the contribution of all migDC subsets 
in the LN, including those that acquire antigen peripherally 
and traffic antigen to the LN, and those that have already ar-
rived in the skin-draining LN at the time of antigen capture in 
the LN. Again, at both 5 and 0.5 µg of s.c. CD205-gag p24 
all migDCs were dispensable. (Fig. 5 B). Absence of migDCs 
in the skin-draining LNs of individual CCR7/ mice com-
pared with B6 control mice was confirmed at the time of har-
vest (Fig. 5 A and not depicted). Again, irrespective of Flt3L 
treatment we noted a trend of higher mean ex vivo CD4+ 
IFN- responses in lymphoid organs and in tissue (spleen, LN, 
and lung) and in vitro recall T cell proliferation in CCR7/ 
versus control mice. To ensure s.c. immunization did not by-
pass migratory DCs, we examined low-dose CD205-gagp24 
i.d. immunization into the flank (Fig. 5 C). Mice lacking 
CCR7 had significantly higher CD4+ T cell IFN- levels in 
the draining proximal LN (P < 0.0001) and distally in spleen 
(P < 0.05) and nondraining LNs (unpublished data). These 
data suggested that blockade of CCR7-dependent DC migra-
tion to the LN enhances, not impairs, immunity.
To determine whether migratory DCs were requisite for 
CD8 immunity, we also tested s.c. CD205-OVA immuniza-
tion. Again, no loss of CD8+ T cell proliferation in CCR7 KO 
mice was observed (Fig. 5 D). CCR7 KO mice may have 
defects in T reg cell activity that could support enhanced 
priming (Menning et al., 2007). To restrict CCR7 deficiency 
to DCs, we generated mixed bone marrow chimeras with 
CD45.1 and ZBTB46 DTR or CCR7 and ZBTB46DTR. 
Zbtb46 is a recently described cDC-specific transcriptional 
factor that distinguishes classical DCs from other mono-
nuclear phagocytic lineages and from plasmacytoid DCs 
(Meredith et al., 2012; Satpathy et al., 2012). When uncom-
pensated CCR7 loss was restricted to migDCs, there was no 
loss of immunity (Fig. 5 E). These mice could not be used to 
evaluate whether CCR7 deficiency in migDCs leads to in-
creased immunity because ZBTB46 affects both tissue-resident 
and lymphoid-resident cDCs. Therefore, CCR7-dependent 
migratory DCs are not required for immunity.
ZBTB46-dependent cDCs are required for priming
To further clarify the cellular requirements for s.c. priming, 
we made BM chimeras comparing chimerization of control 
(CD45.1) BM to BM from several different DTR-expressing 
lines after DT treatment to deplete distinct cell populations. 
Chimerization was needed to avoid toxicity associated with 
DT administration directly to CD11c-DTR mice, although 
irradiated chimera recipients are older and generally have 
and we observed more rapid antigen capture by migDCs in 
LNs. Langerin 103+ DCs are dermal migDCs that cross-prime 
to virus (Bedoui et al., 2009b), yet a role in viral vaccine 
priming has not been established. To address this, we used 
Langerin-diphtheria toxin (DT) receptor (DTR) mice (LDTR), 
where expression of the DTR in Langerin+ cells permits de-
pletion of Langerin+ DCs by DT treatment (Noordegraaf 
et al., 2010). In LDTR mice, a single dose of DT leads to dele-
tion in the skin-draining LN of some Langerin+ CD8+ 
cDCs (Kissenpfennig et al., 2005), and all CD103+ Langerin+ 
dermal DCs and LCs (Bennett et al., 2005; Noordegraaf et al., 
2010). Robust depletion of Langerin+ migDCs occurred after 
DT administration in both untreated and Flt3L-treated mice 
including LC and CD103+ migDCs (Fig. 4, A and B). DT was 
administered 3 d and 1 d before vaccination during prime and 
boost phases (schema, Fig. 4 C). At 5 µg of CD205-gag p24 
with adjuvant, all Langerin+ DCs were dispensable for effi-
cient vaccine priming at baseline, and their deletion did not 
diminish CD4+ vaccine responses, irrespective of Flt3L treat-
ment when compared with controls administered DT at the 
same dosing scheme. In some Flt3L-treated groups and in all 
PBS controls (LNs, Spleen), we were surprised to note signifi-
cantly higher direct ex vivo effector responses in LDTR mice 
compared with WT controls as measured by CD4 IFN- pro-
duction (Fig. 4, D and F).
Soluble protein immunization lacked a discernible IFN- 
or CFSE response at 0.5 µg when compared with adjuvant 
alone, establishing CD205-targeted immune response speci-
ficity that occurred at 0.5 µg (Fig. 2 A). Under high antigen 
conditions, we reasoned that cDCs might capture excess anti-
gen despite the loss of Langerin+ populations. At 0.5 µg, 
s.c. immunization was likely not mediated through DCs in the 
spleen because splenectomized and control mice had equiva-
lent responses (unpublished data). To test if Langerin+ DCs 
were required for immunization under antigen-limiting doses, 
we also immunized DTR and control mice with 0.5 µg of 
CD205-gag p24 and adjuvant (Fig. 4, D–H). We were sur-
prised to note no loss of response occurred after DT treatment, 
suggesting that Langerin+ DC subsets were not required, even 
under dose-limiting concentrations. Instead, we observed a trend 
that the immediate ex vivo IFN- response in LN, spleen, and 
lung was generally significantly higher upon ablation of Lan-
gerin+ DCs (Fig. 4, D–F). In vitro CD4+ proliferation to 
CD205-p24 was not diminished in LDTR mice (Fig. 4 G). 
We also observed higher ex vivo IgG titers after deletion of 
Langerin+ subsets, irrespective of Flt3L treatment, irrespective 
of both Flt3L and high (not depicted) or low antigen dose 
(Fig. 4 H). CD8+ immunity to CD205-OVA was preserved 
in Langerin-DTR versus B6 control mice treated with DT 
(Fig. 4, I–K) and a subtly heightened trend was again observed. 
This was probably not caused by enhanced antigen uptake by 
cDCs in LDTR versus control mice (Fig. 4 L). Collectively, 
these data suggest that Langerin+ DCs, including LCs and 
Langerin+ CD103+ DCs, were dispensable to CD4 or CD8 
T cell priming and greater ex vivo effector and humoral immu-
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A and B). A significant reduction in clonal expansion was ob-
served after 4 d of culture in Z-DTR and in CD11c-DTR 
compared with control chimeras and littermate chimeras that 
had not received DT (Fig. 6 C, blue). In L-DTR chimeras, 
although radioresistant populations such as LCs were spared, 
radiosensitive Langerin+ CD103+ migDCs were deleted. Con-
sistent with the observation that L-DTR unchimerized mice 
had heightened immunity, depletion of Langerin+ CD103+ DCs 
lower overall vaccine responses. We compared BM chime-
ras: CD45.1→CD45.2 (control), Langerin-DTR (L-DTR)→
CD45.2, CD11c-DTR→CD45.2, and Zbtb46 DTR 
(Z-DTR)→CD45.2. IFN- T effector responses were im-
paired ex vivo in LN and spleen in Z-DTR and CD11c-DTR 
donor BM chimeras but not in L-DTR or CD45.1 controls 
with 0.5 µg of CD205gag-p24 and GLA. The observed re-
duction was comparable to p17 controls (red vs. black; Fig. 6, 
Figure 4. Langerin+ DC, including LCs and 
CD103+ DC, are not required for CD4 s.c. 
protein immunization. (A) Deletion of  
Langerin+ migratory DC subsets after a single 
dose (1 µg) DT administered 24 h before har-
vest. (B) Deletion of Langerin+ subsets in 
Flt3L-treated Langerin DTR mice administered 
Flt3L daily. DT was administered 3 and 1 d 
before harvest at day 8. (C) Schema: 1 µg DT 
was administered to Langerin DTR mice versus 
WT controls day 3 or 1 to s.c. vaccine 
prime or boost with GLA plus 5 or 0.5 µg 
CD205 gag-p24. (D) Spleen, (E) LN, (F) Lung- 
intracellular cytokine staining. (G) CD4+ IFN-+ 
CFSE divided cells in Langerin DTR versus 
C57BL/6 WT mice in Flt3L-treated (red Flt3L 
treated, 1 representative experiment at 5 µg, 
or pooled from 2–3 independent experiments 
at 0.5 µg) or PBS-treated controls (blue, 
pooled from 2–3 independent experiments at 
5 or 0.5; ^, P ≤ 0.1; *, P ≤ 0.05; **, P ≤ 0.01; 
***, P ≤ 0.001). (H) Serum HIV gag-p24 IgG 
titers in Langerin DTR versus WT mice treated 
with Flt3L versus PBS (one representative 
experiment of three (n = 5 mice), *, P ≤ 0.05, 
**, P ≤ 0.01, ***, P ≤ 0.001). (I–K) 1 µg DT was 
administered to Langerin DTR mice versus WT 
controls day 3 or 1 to vaccine prime or 
boost with s.c. polyIC(LC) plus 0.5 µg CD205 
OVA. In vitro challenge of OVA versus control 
peptide. (I) Spleen, (J) LN intracellular cytokine 
staining, and (K) CD8+ IFN-+ CFSE divided 
cells (n = 4–7 mice total per group pooled 
from 2 independent experiments). (L) Capture 
of CD205 by classical CD8+ LN cDCs 3 h 
after footpad injection (7.5 µg total) is im-
proved by Flt3L but not altered after Langerin+ 
DC ablation. 1 µg of DT was administered at 
3 and 1 d, with injection and harvest on 
day 0, after 9–10 d of PBS or Flt3L treatment. 
(left) WT (green), Langerin-DTR mice (red). 
(right) % CD205uptake by cDCs and migDCs 
in the popliteal LNs. Pooled from two inde-
pendent experiments (n = 5–6 mice total;  
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Figure 5. Blockade of migratory DCs does not impair immunity after s.c. or i.d. protein immunization. (A) Representative gating of inguinal LN 
taken from CCR7/ and Flt3L-treated and untreated vaccine mice. (B) CCR7/ mice versus B6 controls were immunized with 5 or 0.5 µg of CD205 
gag-p24 in separate experiments (n = 3 mice per group). Error bars show mean ± SEM. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001. Red, Flt3L treated; blue, PBS 
treated. Intracellular cytokine staining for spleen, LN, and lung parenchyma and CFSE dilution of splenocytes after 4 d in culture with p24. (C) i.d. immuni-
zation with 0.5 µg CD205 gag-p24: proximal draining LN and spleen intracellular cytokine staining and CFSE dilution of splenocytes after 4 d in culture 
with p24. Pooled from 3 independent experiments of n = 5 mice per group. Error bars show mean ± SEM. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001). (D) CD8+ 
CFSE divided IFN- T cells after DEC-OVA SQ immunization. Pooled from 2 experiments, n = 4–5 mice per group. Error bars show mean ± SEM. *, P ≤ 0.05; 
**, P ≤ 0.01; ***, P ≤ 0.001. (E) Mixed bone marrow chimera after SQ immunization with 0.5 µg CD205 gag-p24 in the presence or absence of DT, CFSE 
dilution shown. Pooled from 2 independent experiments with n = 4–5 mice per group for CCR7+ZDTR chimeras compared plus and minus DT; n = 1 
experiment for 5 mice per group for CCR7+CD45.1 plus and minus DT controls. Error bars show mean ± SEM. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001.
in L-DTR chimeras produces heightened ex vivo CD4+ im-
mune responses when compared with CD45.1→CD45.2 
control chimeras.
Z-DTR does not delete monophagocytic lineages or PDCs 
and immunity was lost in Z-DTR mice, suggesting these sub-
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DCs, or macrophages (Fig. 7 A). We observed similar clustering 
of skin-resident DCs in humans when compared with their 
developmental counter parts in blood (Fig. 7 B). To further in-
vestigate this, we sorted three subsets of migDCs and CD8+ 
cDCs from the skin-draining LNs from Flt3L-treated mice, 
seeking transcripts commonly expressed across three migDCs 
subsets at twofold differential expression when compared with 
LN-resident CD8+ DCs. We identified common up-regulation 
of genes associated with immune suppression across all skin 
DC subsets when compared with lymphoid-resident cross-
presenting DCs mouse (Fig. 7 C). To determine if this occurs 
in people, we also analyzed transcripts from three subsets of 
human migDCs isolated from skin versus blood BDCA3+ 
cross-presenting DCs that were available in the NCBI Gene 
Expression Omnibus (GEO; see Materials and methods; Haniffa 
et al., 2012). We observed overlap in the genes expressed in 
the skin-resident or skin-migrated DCs across both species 
(Fig. 7 C). We performed our study in Flt3L-treated mice. 
Prior work has demonstrated immune dampening genes in a 
murine CD103+ migratory lung DC subset when compared 
monocyte-derived DCs, and macrophages were not required 
for immunization, we examined the CD11b-DTR mouse ver-
sus wild-type. We observed no significant difference in prim-
ing between groups after DT administration, further excluding 
the contribution of these cells (Fig. 6, D–F) and controlling 
for the effects of DT administration. These data suggest 
Zbtb46- and Flt3L-dependent cDCs mediate CD205gag-
p24 priming.
migDCs closely cluster and share expression of immune-
dampening genes, and pathways, across species
We were intrigued by the surprising yet consistent observation 
that deletion of one or multiple subsets of Langerin+ migratory 
DCs seemed to enhance immunity. Also, collective blockade 
of skin DC migration enhanced the immune response to prim-
ing in vivo; this appeared to occur irrespective of the presence 
of Flt3L, suggesting migratory DCs might be acting in concert 
to suppress immunity. We observed close principal component 
analysis clustering of migDCs to each other when compared 
with cross-presenting cDCs, monocytes or monocyte-derived 
Figure 6. ZBTB46-dependent classical DCs 
are required for s.c. protein immunization. 
(A–C) CD45.2 mice were irradiated and reconsti-
tuted with bone marrow as indicated. Chimeras 
received DT on day 3 and 1 to prime and 
boost immunization with 0.5 µg CD205 gag-
p24. Intracellular cytokine staining immediately 
ex vivo for (A) Spleen and (B) LN. Black shows 
staining for p17 peptide control (plus DT) versus 
red or blue (plus DT) p24 peptide challenge. 
(C) CFSE dilution of splenocytes after 4 d in cul-
ture. (A–C) Pooled from 4–5 independent experi-
ments (n = 3–5 mice per group, based on survival 
after DT administration). No DT controls (blue) 
performed once across all 4 groups (n = 4–5 mice 
per group). Error bars show mean ± SEM. ^, P ≤ 0.1; 
*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001). (D–F) 
CD11b DTR versus B6 control mice were admin-
istered DT on day 3 and 1 to prime-boost 
immunization with 0.5 µg CD205 gag-p24.  
CFSE dilution of splenocytes after 4 d in culture 
(D) and intracellular cytokine stainings (E–F). 
Black shows staining for p17 peptide control  
(plus DT), red or blue (plus DT) show p24 chal-
lenge in wild-type and controls. One representa-
tive experiment of n = 4–5 mice per group. Error 
bars show mean ± SEM. *, P ≤ 0.05;  
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Figure 7. Migratory DC subsets cluster together and share higher expression of immune dampening genes and down-regulation of genes 
associated with DC activation when compared with cross-presenting DCs in mouse and human. (A) PCA on twofold change (relative to LN CD8+ 
cDCs) or greater in the top 15% of all genes (n = 1,290) genes for 3 individual migratory DC, versus LPS-treated CD205+ cDCs, DC-SIGN+ monocyte-
derived DCs, and macrophages (mouse); n = 3 or 4 independent sorting experiments and sample replicates. (B) PCA on twofold change (relative to 
BDCA3+ or BDCA1+ blood DCs) or greater in the top 15% of all genes (n = 920) for human skin-resident versus blood DC and monocyte subsets. (C) Genes 
shared across all three migDCs subsets with twofold or greater difference compared with CD8 cDCs (mouse) or blood BDCA3+ DC humans: (left) mouse 
and (right) human skin DC subsets. * denotes the fold difference was under the threshold cut off of twofold in at least one of three migDC subsets.  
(D) Cross-species IPA. 227 genes commonly up-regulated by twofold or greater across all 3 migratory skin DC subsets compared with classical cross-
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identified Flt3, ZBT46-dependent classical DCs as central to 
T cell priming to HIV gag-p24. Strikingly, despite enhanced 
antigen capture and Flt3L dependence, migDCs, including 
Langerin+CD103+ DCs, dampen the immune response in vivo 
and share common gene signatures related to blockade of DC 
and T cell activation. Our data reveal Flt3 signaling is central 
to productive immunity via classical DCs and suggest Flt3L 
may have therapeutic potential when coupled to DC-targeted 
and soluble protein vaccines, as Flt3L enhanced immunity in 
multiple settings.
During immunization, changes in the distribution and com-
position of DCs occur. LN-resident and migDCs redistrib-
ute their numbers in the skin-draining LN, a change largely 
accounted for by an increase in the population of Langerin 
dermal DCs (Kastenmüller et al., 2011). Although tightly reg-
ulated in the steady state (Shadle et al., 1989; Langley et al., 
1993), we detect Flt3L immediately after s.c. delivery of pro-
tein immunization and note Flt3L administration alters the 
composition of cDCs and migDCs in the skin-draining LNs. 
Flt3 receptor signaling is also necessary for productive immu-
nity. Our data therefore suggest Flt3–Flt3L interactions are likely 
central to changes in the composition of the LN DC com-
partment after immunization and requisite for immunity. As 
previously observed in spleen (Bozzacco et al., 2010; Sathe 
et al., 2011), we note that Flt3L expands PDCs and cDCs in 
skin-draining LN, with bias to CD8 CD205+ cross-presenting 
cDCs (Fig. 3, A and B). Flt3L bias to LN-resident cross- 
presenting DCs and improved antigen capture by DCs are 
mechanisms that may support enhanced protein immuniza-
tion. Indeed, newly formed CD24+ Flt3L-dependent precur-
sors to CD8+ spleen DCs induce stronger viral recall than 
CD8+ DCs (Bedoui et al., 2009b). cDCs from Flt3L-treated 
mice demonstrate a higher percentage of in vitro antigen cap-
ture due to a higher fraction of CD8+ CD205+ DCs being 
represented (Fig. 3, B and C). This does not exclude the pos-
sibility Flt3L could alter lymphatic antigen delivery, but sug-
gests differences in composition may be responsible for the 
observed effect in vivo.
Robust mucosal immunity is of particular importance to 
preventing the pathogenesis of certain lentiviral infections, such 
as HIV. Preferential depletion of CD4+ T cells has been noted 
in the intestinal lamina propria during acute HIV infection 
(Brenchley and Douek, 2008). Flt3L enhances both CD4+ and 
CD8+ mucosal immunity in peripheral sites, including lung 
parenchyma, small intestinal lamina propria, and skin (unpublished 
data). Enhanced immunity was versatile and occurred with 
different antigens, microbial mimics, soluble and DC-targeted 
protein immunization, and increased serum IgG, lymphoid, and 
mucosal T cell responses. Coupling Flt3L to both soluble and 
DC-targeted protein vaccines with appropriate adjuvant for 
cross-presenting cDCs will likely be of clinical benefit.
Given a requirement for FLK and Zbtb46 with exclusion 
of migDCs, pDCs, monocytes, and macrophages, we demon-
strate that Flt3L- ZBTB46-dependent cDCs are central to s.c. 
priming. T cell priming via LN-resident CD24+ CD8 DCs 
is consistent with our observation that Flt3L improved 
with CD8+ lung LN DCs (Miller et al., 2012). For additional 
validation, we compared our dataset (Illumina) to additional 
datasets from skin DC subsets and LN CD8+ cDCs available 
in the GEO (see Materials and methods), which were per-
formed by an independent consortium on a different array 
platform (Affymetrix) and in the absence of Flt3L treatment 
(Fig. S3). We observed the same trend, which was unaltered by 
Flt3L treatment. Murine transcripts included SOCS2, PIAS3, 
PD-L1, ITGB8, and Spred1, CD63, IL4i1, IL15R, Tmem176A, 
and Tmem176B. ITGB8 induces the immunosuppressive 
cytokine TGF (Travis et al., 2007). Knockdown of the 
tetraspanin CD63 in APC enhances T cell function (Petersen 
et al., 2011). Tmem176A and 176B binding partners inhibit 
DC maturation (Louvet et al., 2005; Condamine et al., 2010). 
The immature state of DCs is associated with silencing of an-
tigen specific T cell responses, induction of T regulatory cells, 
and tolerance to self (Steinman et al., 2003; Ohnmacht et al., 
2009). CCL5 is involved in DC migration (Sallusto et al., 2000), 
dampens airway hyperresponsiveness, and is essential for sup-
pressor functions of T reg cells (Chang et al., 2012). MigDCs 
also commonly shared reduced expression of gene products 
and pathways associated with DC activation, function, and 
regulation, including Clec9A, XCR1, and CD36. Diminished 
expression of Clec9A may prevent T cell activation (Zhang et al., 
2012). The lymphotactin receptor XCR1 is found on CD8+ 
cross-presenting DCs. The XCL1–XCR1 axis controls CD8+ 
T cell cytotoxicity against antigen (Dorner et al., 2009). 
CD36 down-regulation may alter DC maturation as binding 
of erythrocytes infected with malaria to DCs via CD36 sig-
nificantly inhibits DC maturation (Urban et al., 1999), and 
antibodies against CD36 modulate DC function (Urban et al., 
2001) resulting in failure to prime T cells.
To hone in on commonly regulated pathways across spe-
cies, we performed Ingenuity Pathway Analysis (IPA) of genes 
shared in the migratory DCs of mouse and humans (Fig. 7 D). 
SOCS2, IL-15, and PD-L1 and FAS pathways were observed 
as central to differential migDC gene expression (Fig. 7 D). 
SOCS2 may act on DCs directly to block activation through 
STAT3 and NF-B signaling (Posselt et al., 2011). In human 
DCs, SOCS2 acts as a negative regulator of DC activity that is 
normally expressed after TLR-induced DC activation to 
counter-regulate DCs (Posselt et al., 2011). IL4i1 has a role in 
antigen processing and presentation (Boulland et al., 2007) and 
inhibits T cell proliferation (Lasoudris et al., 2011). PD-L1 di-
rectly inhibits T cell function (Butte et al., 2007; Zhang et al., 
2012). Convergence on IL-15 signaling may suggest skin DC–
mediated control of NK cell function (Castillo et al., 2009).
DISCUSSION
s.c. immunization is one of the most potent and common 
forms of immunization. Nevertheless, it remains incompletely 
understood in vivo, limiting the design and development of 
clinical agents to enhance immunity. To elucidate the role of 
different DC subsets in immune priming, we simultaneously 
examined development, antigen capture, gene expression 
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subsets carry high concentrations of processed antigens to the 
LN inner and outer paracortex near HEVs (Bajénoff et al., 
2003; Kissenpfennig et al., 2005) and arrive in the LN later 
after immunization (Itano et al., 2003). That we observe en-
hanced antigen capture by migDCs in LNs is consistent with 
prior observations of soluble antigen pE–I–Ab complexes 
detected on skin-derived DCs already present in the LNs as 
early as 30 min after s.c. antigen injection (Itano et al., 2003). 
Based on the early kinetics of peptide complex detection, 
migDCs in LN were thought to initiate T cell priming. How-
ever, when the injection site is removed 5 h after s.c. priming, 
preventing the arrival of additional migDCs from periphery 
to LN, clonal proliferation is not impaired, suggesting redun-
dancy of migDCs that acquired antigens in the periphery and 
traffic into the LN. However, injection site removal studies 
cannot exclude the contribution of preexisting LN-resident 
migDCs (Itano et al., 2003). Rather, when we tested CCR7/ 
mice where migDCs are entirely absent from the LN at the 
time of priming, we observe enhanced not diminished in vivo 
immune priming supporting a role for migDCs at the LN in 
dampening immunity and further supported by their com-
mon transcriptomics program.
Previous studies addressing DC subset contributions have 
largely examined the CD4+ T cells response to s.c. OVA im-
munization (Allenspach et al., 2008). In this system, immune 
responses depended on radio-resistant skin DCs (i.e., mainly 
LCs) in the draining LNs. Differences in our observations 
from such work may result from several notable differences in 
the model systems used, including the antigen (HIV gag-p24 
vs. OVA), the adjuvant (microbial mimic vs. complete or in-
complete freund’s adjuvant), deliver strategy (DC-targeted vs. 
nontargeted), differences in the naive polyclonal repertoire 
in our study versus intravenous adoptive transfer of a single- 
affinity clone (OT-II), and the model system used to test the 
contribution of migDCs (restricted migration and complete 
absence in the LN in CCR7/ or DTR depletion [our 
study] versus normal migration capacity of migDCs but with 
impaired MHCII presentation [Allenspach et al., 2008]). Ad-
ditional work using OT-II T cell transfer and immunization 
with chemically coupled CD205-OVA in the CCR7/ 
versus control mice observed a diminished T cell response in 
CCR7/ mice (Ohl et al., 2004). Therefore, the difference 
we observe compared with previous studies with OVA and 
OT-II is most likely related to the nature of the antigen and 
uniform T cell repertoire in the setting of transgenic models 
rather than antigen delivery (DC targeting), adjuvant, and the 
model system used to distinguish migDCs from LN-resident 
DCs. Indeed, in prior experiments when the concentration of 
OVA was increased the requirement for migDCs was relieved 
(Allenspach et al., 2008). Thus, dependence for the migDCs 
in the OVA transgenic system may relate to specifics of that 
system, such as affinity of the clone, low-dose antigen, the 
number of peptide MHCII complexes, the distribution of in-
travenously transferred transgenic T cells, and competition of 
naive transgenic cells for antigen. Consistently, migDCs failed 
to induce delayed proliferation of OT-II cells in the absence 
immunization with either TLR 3/MDA5 (polyIC[LC]) 
and TLR 4 (GLA-SE) microbial mimics as adjuvant. Flt3L- 
dependent CD24hi DCs from the spleen and BM cultures ex-
press higher transcripts for TLR3 and some TLR4, whereas 
the CD11b+ subset expresses predominantly TLR4 and no 
TLR3 (Naik et al., 2005). The requirement for cDCs and 
not migDCs is not likely caused by TLR restriction because 
CD103+ dermal DCs express higher levels of TLR3 ( Jelinek 
et al., 2011) but are dispensable for immunization with 
polyIC(LC). Finally, our observations in CCR7/ mice, also 
may suggest monocyte-derived DCs are not required in the 
LN during priming because they require CCR7 for LN entry 
(Cheong et al., 2010). Although GLA-SE is a microbial mimic 
of LPS, and LPS induces monocyte-derived DCs, we observe 
that GLA-SE may act as adjuvant independently of monocyte-
derived DCs in the skin-draining LNs. This was further 
validated using CD11b DTR mice in which deletion of 
monocytes and monocyte-derived DCs, but not CD8+ 
CD205+ cDCs, occurs (Choi et al., 2011), which did not im-
pair CD4+ IFN- responses.
Our data support a functional and genetically programmed 
role for migDCs in dampening immunity. Current vaccine 
design efforts are centered on targeting antigen to skin DCs 
and may inadvertently trigger a program of immune suppres-
sion. At high and limiting dose CD205-gag p24, we do not 
observe a requirement Langerin+ DCs in s.c. immunization. 
Rather we observe enhanced T and B cell immunity. En-
hanced immunity to s.c. and i.d. antigen are observed in the 
complete absence of skin DC migration to the draining LNs. 
Consistent with a role in dampening immunity in vivo, three 
individual skin DC subsets share common expression of genes 
associated with tolerance when compared with lymphoid and 
blood cross-presenting DCs. These included common pro-
grams shared across species that block DC migration and 
activation, and those involved in direct inhibition of T cell 
activation, such as PD-L1. Thus, the immune response likely 
results from a complex interplay of tolerizing and immuniz-
ing DC activity in LNs. The cues that dictate when migDCs 
are poised to induce tolerance versus immunity to self and 
nonself-antigens remain to be further investigated. These cues 
may be conferred by the cutaneous or peripheral microenvi-
ronment and likely extend beyond hematopoietic lineage 
specification. Our study suggests Langerin+CD103+ DCs 
from tissue directly oppose the activity CD8 cDCs in LNs 
in vivo despite common origin, shared developmental path-
ways, and irrespective of developmental potentiation with 
Flt3L. Indeed, we find migDCs from both Flt3L-treated 
and untreated mice share elevated expression of immune-
dampening gene signatures and pathways (Fig. 7 and Fig. S3).
In contrast to a deterministic model in which distinct 
populations of DCs are developmentally programmed, the 
role of different DC subsets in priming and tolerance could 
relate to their spatial and temporal distribution in the LN, tis-
sue residence, and antigen access. cDCs lie close to the LN 
reticular system, or conduits, where they rapidly uptake and 
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mice were generously provided by B. Malissen, bred as homozygotes at The 
Rockefeller University, and have been previously described (Kissenpfennig 
et al., 2005). BM chimeras used 8–9-wk-old irradiated recipients (500 cGy 
plus 550 cGy) with 3 h between irradiations; cell suspensions of BM were 
injected intravenously immediately after (3 × 106 BM cells transferred per 
recipient). Mice were maintained after radiation on antibiotic supplemented 
food (TestDiet) for 12 wk before use. All mice were housed in specific patho-
gen–free conditions. Protocols were approved by the Rockefeller University 
Animal Care and Use Committee.
Tissue harvest and cell preparation of DC. 6–8-wk-old C57BL/6 F or 
Langerin-GFP mice were injected s.c. to the flank with endotoxin-free 
(<0.0064 EU/mg), GMP grade, recombinant human Flt3L (Celldex) at 
10 µg/mouse/day diluted in sterile PBS for 10–14 d. For sorting skin DC sub-
sets, Flt3L-treated Langerin GFP mice were used to obtain sufficient num-
bers of migratory DCs from the skin-draining LNs. Skin-draining LN and 
spleen was isolated from individual mice, teased or ballooned, and incubated 
for 25 min at 37°C in Collagenase D (400 U/ml, Roche) in Hanks’ Balanced 
Salt Buffer (Invitrogen). After incubation, 0.5 M EDTA was added to a final 
concentration of 10 mM EDTA for disruption of DC–T cell complexes and 
the sample was incubated for an additional 5 min at 37°C. For spleen cell 
preparation, ACK lysis of red cells was performed. Undigested fibrous mate-
rial was filtered through a 70-µm cell strainer. Subsequent washed were per-
formed with ice-cold PBS with 2% FCS. For crawl-out assay, individual ears 
were harvested, washed in 70% EtOH and split dermal side down into com-
plete-RPMI media. At 72 h, cell suspensions were isolated and filtered. The 
pellet was washed twice and incubated in Fc block with 2% rat serum before 
cell surface marker antibody staining.
After size, live/dead, and exclusion criteria (CD3, CD19, NK1.1 exclu-
sion), DC subsets were sorted as described (Fig. 3 and Fig. S2). RNA was pre-
pared by standard methods using TRIzol (Invitrogen) and further purified 
using RNeasy MinElute clean up (QIAGEN). Purity analysis was done by 
nanodrop and Eukaryote Total RNA Pico Series II (Agilent). RNA was ampli-
fied and hybridized on the Illumina MouseRef-8 v2.0 Expression BeadChip.
Vaccination protocol. Age, gender-matched control, and experimental mice 
were injected daily during both the prime and boost phase by i.p. injection 
with Flt3L, as above, in sterile PBS, or by PBS alone (control) for 10 d. At day 8, 
CD205-gag p24 or CD205-OVA was injected s.c. into the footpad or by 
the i.p. route, as indicated with 20 µg of GLA-SE (Immune Design) or 25 µg 
of polyIC stabilized with poly-L-lysine (poly IC[LC]; Longhi et al., 2009).
Boost vaccination was administered exactly 4 wk later. For s.c. priming 
to CD205-gag p24, mice in all groups were sacrificed 7 d after immuniza-
tion. For s.c. priming to CD205-OVA, mice were sacrificed at day 11after 
boost for IP priming at 21 d. In mice vaccinated to CD205-gag p24, peptide 
challenge with p24 pools or p17 (control) pools at 1 µg/ml for intracellular 
cytokine staining with 2 µg/ml anti-CD28 antibody was added, and at 
0.05 µg/ml for CFSE 4 d cultures. For mice vaccinated to CD205-OVA, 
OT-I and OT-II peptides were pooled versus p24 (control) at 1 µg/ml for ICS 
with 2 µg/ml anti-CD28 antibody, and for CFSE cultures at 0.05 µg/ml.
T cell isolation for proliferation assay or intracellular cytokine stain 
(spleen, lungs, and LN). Individual vaccinated mice were sacrificed, and 
serum collected by cardiac bleed with separation of serum from heme by 
centrifugation at 13,000 rpm in BD microtainer serum separator tubes (ref. 
365956) in a table-top rotor (Eppendorf 5417R) at 4°C. Intracardiac perfu-
sion was performed with PBS into the right ventricle to balloon the lungs 
and flush leukocytes and RBCs from the pulmonary circulation. Individual 
lung lobes were dissected, taking care to avoid the mediastinal LN, ballooned 
with Collagenase D, and then further dissociated with pressure using the end 
of a 5-ml syringe, followed by incubation at 37°C for 20 min. 10 mM EDTA 
was added for the last 5 min of incubation. ACK lysis was performed as above. 
Spleens and LN were harvested in RPMI complete media with 5% FCS, 
mashed between 2 sterile glass slides, washed with RPMI complete media, 
and then filtered through a 70-µM filter. Spleen samples but not LNs went 
of lymphoid-resident DC antigen presentation (Allenspach 
et al., 2008), supporting our observation LN-resident DCs are 
required to initiate immunity and that lymphoid-resident 
DCs selectively trap antigen-specific lymphocytes in the 
draining LN (Itano et al., 2003). Our initial observation that 
migratory DCs dampen the immune response to high- and 
low-dose antigen was validated with four selective DC abla-
tion models and transcriptome analyses.
Lastly, we note that CCR7 is dispensable on both T cells and 
DCs for productive immunity. Though migDCs are entirely 
CCR7-dependent, naive T cell entry into LN is partially de-
pendent on CCR7 and reduced to 30–50% of wild-type levels 
in peripheral LNs (Förster et al., 1999). T cells can be classified 
as naive central memory (TCM) CD45RA CCR7+, effector 
memory (TEM) CD45RA CCR7 or terminally differentiated 
effector cells (TEMRA) CD45RA+ CCR7 (Sallusto et al., 1999; 
Sallusto and Lanzavecchia, 2009; Pepper et al., 2010). That 
CCR7 dependence was not observed on T cells may relate to 
the observation in vaccinia virus and yellow fever vaccines that 
memory T cells within 2 wk of priming are predominantly 
CCR7 and exhibit strong proliferation in vitro, suggesting a 
lack of terminal differentiation (Ahmed and Akondy, 2011).
Advances in immunotherapy to block immunosuppres-
sion include CTLA-4 and PD-L1 blockade, and dramatically 
expand the therapeutic window for immune priming. Protein 
immunization offers a safe and efficacious strategy. We dem-
onstrate the Flt3 pathway is central to protein immunization 
and can be exploited to potentiate immunity via cDCs. Our 
data further reveal that a robust T cell and humoral immunity 
to protein immunization with clinically relevant vaccines, and 
with a polyclonal T cell repertoire, is centered on ZBTB46- 
and Flt3L-dependent cDCs. We establish skin-derived migDCs, 
including Langerin+ 103+ DCs, are not required at the LN 
for s.c. protein vaccination immunization. Instead these popu-
lations collectively and individually dampen immunity and 
share common expression of genes associated with immune 
inhibition. Though Langerin+CD103+ DCs of the skin share 
developmental origin with CD8 cDCs in lymphoid tissue, 
they may be conditioned by tissue microenvironment to in-
hibit DC and T cell activation. This cannot be overcome by 
enhancing their numbers, antigen capture, or developmental 
conditioning. Thus, future immunization strategies for the 
clinic will couple likely protein immunization and Flt3L treat-
ment to target antigen to, and simultaneously potentiate the 
development of and antigen capture by, LN-resident cDCs.
MATERIALS AND METHODS
Mice, chimerization, and deletion. C57BL/6 mice (B6) were purchased 
from Taconic Labs or bred at The Rockefeller University. The Langerin-
DTR mouse was developed to distinguish between the functional attributes 
of Langerin+ and other DC subsets (Bennett et al., 2005). 0.5–1 µg DT 
(Sigma-Aldrich) was administered per average 25–30 g mouse as described 
for all DTR-based transgenic strains used, including the CD11b and CD11c 
DTR (Zaft et al., 2005) that were purchased from The Jackson Laboratory. 
CCR7/ mice were bred at The Rockefeller University after purchase from 
The Jackson Laboratory and are described with respect to defects in the skin-
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wash buffer. All extracellular staining was performed in ice cold PBS with 2% 
FCS. FITC painting was performed on the flank with 1:1 1% FITC in ace-
tone/dibutyl phthalate for 18–24 h before harvest.
Flow cytometry and gating. Cells were stained on ice in PBS with 2.0% 
(vol/vol) FCS. LSR II (BD) was used for multiparameter flow cytometry of 
stained cell suspensions, followed by analysis with FlowJo software (Tree 
Star). For vaccine analysis T cells from individual organs were gated by scatter, 
singlets, exclusion of dead cells, CD3+, CD4+ versus CD8+ IFN- and in 
proliferative assays by CFSE low, IFN-+ cells (Fig. S1, sample gating). For 
LN DC subsets, sample gating is depicted (Fig. S2 A).
Microarray analysis, normalization and data analysis. Microarray data 
is available macrophages, monocyte-derived LN DCs, LPS-treated classical 
DCs in LNs, and LNs of Flt3L-treated mice from GEO under accession no. 
GSE53588. Additional murine microarray files (Miller et al., 2012) were 
downloaded from GEO under the accession no. GSE15907 (subset data from 
accession nos. GSM538255–GSM538257 and GSM538268–GSM538279). 
A custom chip technology for Affymetrix Mouse Gene 1.0 ST was created to 
import the raw data into GeneSpring NGS. Human microarray files (Haniffa 
et al., 2012) were downloaded from NCBI Gene Expression Omnibus under 
the accession no. GSE35459 (subset data from accession nos. GSM868894–
GSM868898, GSM868910–GSM868917, and GSM868922–GSM868925). 
A custom chip technology for Illumina HumanHT-12 V4.0 expression Bead-
Chip was created to import the raw data into GeneSpring NGS.
Raw files were preprocessed and normalized using GeneSpring GX Ver-
sion 12.5 RMA algorithm. Resultant data were pooled into groups by vari-
ous subtypes. The results of replicates were averaged. Normalized data were 
filtered for gene encoding regulators with a coefficient of variation of less 
than 0.5 in population replicates. Individual dermal migratory DCs in LNs 
were compared against LN-resident CD8+ DCs, and differentially expressed 
genes of twofolds or more were assessed by variance across the DC popula-
tions with the one-way (ANOVA), corrected for multiple hypotheses testing 
with Benjamini and Hochberg FDR of <0.05.
Statistical analysis. For data reported in vaccine experiments, error bars 
represent the standard error of the mean plotted between 3–5 individual ani-
mals per experiment per replicate. Statistical analysis for ICS and CFSE was 
performed using the Mann-Whitney test between two groups was done 
using Prism software (P > 0.05, not significant [ns], *, P ≤ 0.05; **, P ≤ 0.01; 
***, P ≤ 0.001). For serum Flt3L ELISA detection (Mann-Whitney test) and 
DC expansion (unpaired Student’s t test), error bars represent the SD be-
tween three to five individual mice per group. For serum gag-p24 or OVA 
IgG detection, error bars represent the mean ± SEM and were analyzed using 
an unpaired Student’s t test.
Online supplemental material. Fig. S1 shows the gating schema for in-
tracellular cytokine staining assays. Fig. S2 shows the gating of LN-resident 
DC subsets. Fig. S3 depicts fold change in individual migratory skin DC 
subsets from our Flt3L-treated mice on the Illumina platform, versus Imgen 
consortium data on untreated mice on the Affymetrix platform. Online 
supplemental material is available at http://www.jem.org/cgi/content/full/ 
jem.20131397/DC1.
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through subsequent ACK lysis as described, and were washed twice and 
counted. As described by Trumpfheller et al. (2008) 500K splenocytes were 
incubated for 6 h at 37°C with p24 pooled peptides or p17 pooled peptides 
at a final concentration of 1 µg/ml with 2 µg/ml anti-CD28 antibody (clone 
37.51; American Type Culture Collection). After 1-h incubation, Brefeldin A 
was added to a final concentration of 10 µg/ml for the remaining 5 h to allow 
intracellular cytokine accumulation. For all subsequent steps, cells were 
washed and stained in ice-cold PBS with 2% FCS. For proliferation assays, 
splenocytes were labeled with 1 µM/ml CFSE (Sigma-Aldrich) and plated 
with 0.05 µg/ml p24 or p17 peptide pool. At 72 h, supernatants were har-
vested for cytokine ELISA. At 96 h, cells were isolated, washed, and intra-
cellular cytokine staining was performed as previously described.
Serum gag-specific IgG and Flt3L ELISA. Serum was prepared by car-
diac bleed, followed by serum separation using microtainer tubes (365956; 
BD). Serum gag-specific ELISA was performed by coating NUNC plates 
(Apogent 80040 LE 0903) with 2 µg/ml of gag p24 recombinant protein in 
PBS or ELISA coating buffer overnight at 4°C. Plates were washed 3–5 times 
with PBS and blocked with Blocking solution (1× PBS, 5% goat serum, and 
0.1% Tween-20) for 1 h at 37°C, followed by sample addition at serial 10-fold 
titration (dilutions made into blocking solution) for 2 h at 25°C, followed by 
3–5 subsequent washes. A 1:10,000 dilution of goat anti–mouse IgG HRP 
( Jackson ImmunoResearch Laboratories; 115–035-071) was added according 
to standard protocols for 1 h at 37°C, the plate was washed 3–5 times before 
addition of 100 µl 1X TMB Substrate Solution (eBioscience; 00–4201-56), 
stopped with addition of 2N sulfuric acid, and read at 450/470 nm. Murine 
Flt3L ELISA was performed on serum isolated from 3–5 individual mice 
using the RD mFlt3L ELISA kit (E90038Mu).
Lamina propria isolation. To prepare single intestinal cell suspension, part 
of small bowel including jejunum and ileum or a large bowel (cecum and 
colon) were excised. Peyer’s patches were removed from the small intestinal 
tissue. Intestinal lumen was exposed by a longitudinal incision and the tissue 
was cut to a pasty consistency. Next, intestinal tissues were incubated in 
RPMI with 1.3 mM EDTA (CellGro) on a 37°C shaker for 1 h. The super-
natants containing intestinal epithelial cell (IEC) with some superficial vil-
lous cells, were discarded. Tissue was washed thrice with RPMI to remove 
EDTA. Tissue was digested with 0.2 mg/ml of type IV collagenase (Sigma-
Aldrich) at 37°C for 1 h. Tissue was then homogenized, filtered, and washed. 
The resulting cell suspension was layered on a 44%/66% Percoll (GE Health-
care) gradient and the interface was collected to obtain an enriched mono-
nuclear cell population. Cell were washed and resuspended in complete 
medium at a density of 2–5 × 106 cells/ml. Recall responses were examined 
as described above.
Antibodies, live/dead dye, CFSE, FITC painting, and staining re-
agents. The following reagents were obtained from BD, eBioscience, or Bio-
Legend: anti-Langerin (eBioL31), anti-CD11c (N418), anti–IFN- (XMG1.2), 
anti-CD4 (RM4-5), anti-CD8 (53–6.7), anti-CD11b (M1/70), anti-
CD103 (2 E7), anti–Armenian Hamster IgG Isotype Control (eBio299Arm), 
anti–rat IgG2a Isotype Control (eBR2a), anti-CD3 (500A2), anti-CD45 (30-
F11), anti-CD205 (NLDC-145), anti-EPCAM (G8.8), anti-CD24 (M1/69), 
anti-F4/80 (BM8), anti-CD115 (AFS98), anti-PDCA1 (ebio927), anti-Ly6c 
(HK1.4), anti-B220 (RA3-6B2), anti–I-A/I-E (M5/114.15.2), anti-CD3 
(17A2), anti-CD19 (eBio1D3), and anti-NK1.1 (PK136). AQUA (L34957) 
was from Invitrogen. Cytofix/Cytoperm kit was from BD. CFSE was ob-
tained from Sigma-Aldrich. Anti-CD205 (NLDC-145) was produced in the 
Steinman laboratory and conjugated to Alexa Fluor 488 or 647. Other re-
agents included PBS and FBS (Invitrogen), ACK lysing buffer (BioSource). 
Staining with Langerin and in some experiments for CD205 was performed 
with cell surface and intracellular label. IFN- staining was performed after 
cell surface label of T cell markers by intracellular cytokine staining using 
Fix/Perm and Perm/Wash buffers (BD). Langerin staining was performed by 
intracellular stain with anti-Langerin (L31) as previously described (Cheong 
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